| Project/Area Number |
26462391
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
篠原 信雄 北海道大学, 医学研究科, 教授 (90250422)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2014: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | 前立腺癌 / ダイオキシン受容体 / 芳香族炭化水素受容体 / アンドロゲン受容体 / Indirubin |
|---|
| Outline of Final Research Achievements |
The expression status of the dioxin receptor (AhR) in the cell line including the human prostate cancer was confirmed by Western blot analysis. LNCaP, which is known as prostate cancer cell line, proliferation is controlled for indirubin or 3- Methylcholanthrene (3MC) as a typical AhR ligand, and the proliferation potency and the transcriptional ability of these ligands were confirmed, and androgen receptor (AR) appearance has decreased. The concentration dependency was admitted. Nude mice had been administrated these dioxin ligands through peritoneal injection. So, tolerated dose has been becoming clear. As a result, it was thought that the therapeutic gain to the hormone refractory prostate cancer was expected.
|
